Radiopharmaceutical specialist Cyclopharm (ASX:CYC) has reached a company milestone as Duke University Hospital signs the first commercial contract for the use of Technegas in the US.
Cyclopharm’s Technegas product is a structured ultra-fine dispersion of radioactive-labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700 degrees.
It’s effectively designed to be inhaled by patients via a breathing apparatus to assist with tomography imaging under a gamma or single-photon emission computed tomography (SPECT) camera.
Cyclopharm Managing Director James McBrayer says the company is ‘thrilled’ that Duke will be among the first to offer Technegas to their referring physicians and patients.
“The implementation of Technegas at Duke will be on full commercial terms, as previously communicated to the market, and will be leveraging off Technegas’ wide indication for use approved by the United States Food and Drug Administration (USFDA).”
“The implementation of Technegas at Duke will be on full commercial terms”
The Duke University Hospital is part of the Duke University Health System and serves as a teaching hospital for the university’s School of Medicine.
Duke is one of the 10 locations in the US that participated in Cyclopharm’s recent clinical trial that was submitted as part of its new drug application for Technegas.
Cyclopharm is a radiopharmaceutical company servicing the global medical community. The company is focused on providing nuclear medicine and other clinicians with the ability to improve patient care outcomes.